Co-Development Agreement with SFJ Pharmaceuticals and Development Derivative Liability (Tables)

6 Months Ended

Jun. 30, 2022

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Derivative Liabilities at Fair Value

The following table presents the changes in the development derivative liability:

		Three months ended
	Fair Value Hierarchy Level	June 30, 2022		June 30, 2021
Fair value as of March 31, 2022 and 2021, respectively	3	$	—	$	4,597
Non-cash research and development expense		—		3,547
Cash receipts from SFJ		—		750
Change in the fair value of development derivative liability		—		2,713
Fair value at end of period	3	$	—	$	11,607

		Six months ended
	Fair Value Hierarchy Level	June 30, 2022			June 30, 2021
Fair value as of December 31, 2021 and February 12, 2021 (inception), respectively	3	$	27,726		$	—
Non-cash research and development expense		4,951			5,795
Cash receipts from SFJ		750			1,500
Change in the fair value of development derivative liability		(33,427)			4,312
Fair value at end of period	3	$	—	0	$	11,607